2021
Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program
Akwo EA, Robinson-Cohen C, Chung CP, Shah SC, Brown NJ, Ikizler TA, Wilson OD, Rowan BX, Shuey MM, Siew ED, Luther JM, Giri A, Hellwege JN, Edwards D, Roumie CL, Tao R, Tsao PS, Gaziano JM, Wilson PWF, O’Donnell C, Edwards TL, Kovesdy CP, Hung AM, Program O. Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension 2021, 78: 376-386. PMID: 34148359, PMCID: PMC8364328, DOI: 10.1161/hypertensionaha.120.16181.Peer-Reviewed Original Research
2018
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis
Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Nutrition Metabolism And Cardiovascular Diseases 2018, 28: 582-591. PMID: 29691148, PMCID: PMC5959764, DOI: 10.1016/j.numecd.2018.02.020.Peer-Reviewed Original ResearchConceptsAngiotensin receptor blockersHigh-density lipoproteinToll-like receptorsAnti-inflammatory effectsReceptor blockersCytokine responsesActivation of TLRsSerum amyloid A (SAA) levelsACE inhibitor effectsHigh cardiovascular riskAdvanced kidney diseaseMaintenance hemodialysis patientsInflammatory cytokine responseAnti-oxidative effectsACEI treatmentAtheroprotective actionARB treatmentCardiovascular eventsMaintenance hemodialysisAngiotensin actionCardiovascular riskHemodialysis patientsCellular superoxide productionHDL functionalityKidney disease
2017
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery
Shuey MM, Billings FT, Wei S, Milne GL, Nian H, Yu C, Brown NJ. Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PLOS ONE 2017, 12: e0175292. PMID: 28552948, PMCID: PMC5446112, DOI: 10.1371/journal.pone.0175292.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseCardiac surgery cohortSoluble epoxide hydrolaseCardiac surgeryKidney injurySurgery cohortAcute Kidney Injury Network criteriaIncidence of AKIPostoperative acute kidney injuryPercent of patientsGlomerular filtration rateBody mass indexAssociation of gainsRenal injuryCardiopulmonary bypassWhite patientsMass indexKidney diseaseFiltration ratePharmacological strategiesDiscovery cohortNetwork criteriaVariant carriersSEH activity
2016
Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease
Gamboa JL, Billings FT, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, Roberts LJ, Himmelfarb J, Ikizler TA, Brown NJ. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiological Reports 2016, 4: e12780. PMID: 27162261, PMCID: PMC4873632, DOI: 10.14814/phy2.12780.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseCKD stage 5Peripheral blood mononuclear cellsSeverity of CKDCKD stage 3Kidney diseaseOxidative stressF2-isoprostanesMtDNA copy numberMuscle biopsyMitochondrial volume densitySkeletal muscleDifferent CKD stagesMitochondrial dysfunctionBlood mononuclear cellsStage 3Stage 5Skeletal muscle biopsiesLower mtDNA copy numberMitochondrial DNA copy numberPlasma isofuransCKD stageMuscle dysfunctionMononuclear cellsFunction worsensHigh-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial
Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA 2016, 315: 877. PMID: 26906014, PMCID: PMC4843765, DOI: 10.1001/jama.2016.0548.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overAspartate AminotransferasesAtorvastatinCardiac Surgical ProceduresCreatinineDouble-Blind MethodDrug Administration ScheduleFemaleGlomerular Filtration RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMedication AdherenceMiddle AgedPostoperative ComplicationsRenal Insufficiency, ChronicConceptsAcute kidney injuryMorning of surgerySerum creatinine concentrationPlacebo groupCardiac surgeryStatin treatmentAtorvastatin groupKidney injuryClinical trialsCreatinine concentrationAcute Kidney Injury Following Cardiac SurgeryAdult cardiac surgery patientsCardiac surgery patientsChronic kidney diseaseHours of surgeryPostoperative day 2Day of surgerySafety monitoring boardVanderbilt University Medical CenterUniversity Medical CenterAtorvastatin dailyStatin therapyAtorvastatin treatmentSurgery patientsKidney disease
2008
Association of a CYP4A11 Variant and Blood Pressure in Black Men
Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ, Group A. Association of a CYP4A11 Variant and Blood Pressure in Black Men. Journal Of The American Society Of Nephrology 2008, 19: 1606-1612. PMID: 18385420, PMCID: PMC2488260, DOI: 10.1681/asn.2008010063.Peer-Reviewed Original ResearchConceptsHypertensive renal diseaseRenal diseaseClinical outcomesHigher systolic BPAdverse clinical outcomesWhite individualsRegulation of BPEndogenous arachidonic acidBlack menBaseline proteinuriaCYP4A11 variantsHypertensive nephrosclerosisRenal vasoconstrictorClinical characteristicsCumulative incidenceRenal functionBlood pressureDiastolic BPHigher systolicSystolic BPHigh BPKidney diseasePulse pressureMale miceHypertension